Last reviewed · How we verify
Molybdenum cofactor deficiency type A
Approved treatments
- Nulibry · Sentynl Theraps Inc
Nulibry works by providing a functional molybdenum cofactor to cells, bypassing the genetic defect that causes molybdenum cofactor deficiency type A.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Molybdenum cofactor deficiency type A patent landscape — cliff calendar, originator estates, attackable patents
- Molybdenum cofactor deficiency type A treatment landscape brief
- Molybdenum cofactor deficiency type A treatment updates RSS
Frequently asked questions about Molybdenum cofactor deficiency type A
What drugs treat Molybdenum cofactor deficiency type A?
Tracked treatments include Nulibry.
What is the treatment for Molybdenum cofactor deficiency type A?
Standard treatment for Molybdenum cofactor deficiency type A includes Nulibry. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Molybdenum cofactor deficiency type A patent cliff · Molybdenum cofactor deficiency type A CI report
- Treatment: Nulibry · Sentynl Theraps Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing